Erratum: Hydroxychloroquine with or without Azithromycin in Mild-to- Moderate Covid-19 (New England Journal of Medicine DOI: 10.1056/NEJMoa2019014);Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19

New England Journal of Medicine

Volumn 383, Issue 21, 2020, Pages 2041-2052

  Cavalcanti, Alexandre B ^a,b   Zampieri, Fernando G ^a,b   Rosa, Regis G ^b,l   Azevedo, Luciano C P ^b,c   Veiga, Viviane C ^b,d   Avezum, Alvaro ^e   Damiani, Lucas P ^a   Marcadenti, Aline ^a   Kawano Dourado, Letícia ^a   Lisboa, Thiago ^a,b   Junqueira, Debora L M ^a   De Barros E Silva, Pedro G M ^a,f   Tramujas, Lucas ^a   Abreu Silva, Erlon O ^a   Laranjeira, Ligia N ^a   Soares, Aline T ^g   Echenique, Leandro S ^h,i   Pereira, Adriano J ⁱ   Freitas, Flávio G R ^b,j   Gebara, Otávio C E ^k   Dantas, Vicente C S ^m   Furtado, Remo H M ⁱ   Milan, Eveline P ⁿ   Golin, Nicole A ^o   Cardoso, Fábio F ^p   Maia, Israel S ^a,q   Filho, Conrado R Hoffmann ^r   Kormann, Adrian P M ^s   Amazonas, Roberto B ^t   De Oliveira, Monalisa F Bocchi ^t   Serpa Neto, Ary ^b,i   Falavigna, Maicon ^l   Lopes, Renato D ^f,u   MacHado, Flávia R ^b   Berwanger, Otavio ⁱ   more..

^a Research Institute Cardiac Hospital (HCor)   (Brazil)

^b Brazilian Research in Intensive Care Network   (Brazil)

^c HOSPITAL SÍRIO LIBANÊS   (Brazil)

^d Centro Oncológico BP Beneficência Portuguesa de São Paulo   (Brazil)

^e HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

^f Brazilian Clinical Research Institute   (Brazil)

^g Hospital São Camilo São Paulo   (Brazil)

^h Hospital Moriah   (Brazil)

ⁱ HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^j Hospital Sepaco   (Brazil)

^k Santa Paula Hospital   (Brazil)

^l HOSPITAL MOINHOS DE VENTO   (Brazil)

^m Hospital Naval Marcilio Dias   (Brazil)

ⁿ Hospital Giselda Trigueiro   (Brazil)

^o Clínica de Anestesiologia e Tratamento da Dor Bento Gonçalves   (Brazil)

^p Bruno Born Hospital   (Brazil)

^q Hospital Baia Sul   (Brazil)

^r Hospital Regional Hans Dieter Schmidt   (Brazil)

^s Angiocor Blumenau   (Brazil)

^t EMS Pharma   (Brazil)

^u DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; BILIRUBIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; LIVER ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN;

ABDOMINAL BLEEDING; ADULT; ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; BRADYCARDIA; CLINICAL OUTCOME; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DRUG FATALITY; DRUG SAFETY; EPISTAXIS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PNEUMOTHORAX; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; AGED; BETACORONAVIRUS; BRAZIL; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONAVIRUS INFECTION; HOSPITALIZATION; PANDEMIC; PATIENT ACUITY; TREATMENT FAILURE; VERY ELDERLY; VIRUS PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; AZITHROMYCIN; BETACORONAVIRUS; BRAZIL; CORONAVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; PANDEMICS; PATIENT ACUITY; PNEUMONIA, VIRAL; TREATMENT FAILURE;

EID: 85092459193     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMx200021     Document Type: Erratum

References (18)

1. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323: 1574-81.
2. WHO coronavirus disease (COVID-19) dashboard. Geneva: World Health Organization (https://covid19.who.int/ ).
3. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARSCoV-2 infection in vitro. Cell Discov 2020; 6: 16.
4. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 March 20 (Epub ahead of print).
5. Cloroquina podera ser usada em casos graves do coronavirus. Brazil: Ministerio da Saude, May 25, 2020 (https://www.saude.gov.br/ noticias/ agencia-saude/ 46601-cloroquina-podera-ser-usada-em-casos-graves-do-coronavirus).
6. Ministerio da Saude divulga diretrizes para tratamento medicamentoso de pacientes. Brazil: Ministerio da Saude, May 20, 2020 (https://www.saude.gov.br/ noticias/ agencia-saude/ 46919-ministerio-da-saude-divulga-diretrizes-para-tratamento-medicamentoso-de-pacientes).
7. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; 382: 2411-8.
8. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323: 2493-502.
9. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020; 383: 517-25.
10. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Press release from the chief investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial. June 5, 2020 (https://www.recoverytrial.net/ news/ statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19).
11. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369: m1849.
12. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.
13. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787-99.
14. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971; 44: 793-7.
15. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing (https://www.R-project.org/ ).
16. Vaduganathan M, van Meijgaard J, Mehra MR, Joseph J, O'Donnell CJ, Warraich HJ. Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States. JAMA 2020; 323: 2524-6.
17. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020; 3(4): e208857.
18. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med 2020; 383: 1813-26.